Condition 1: Hypertension. Condition 2: Hyperglyceridaemia. Condition 3: High-density lipoprotein deficiency. Secondary hypertension, unspecified Pure hyperglyceridaemia Lipoprotein deficiency
Conditions
Interventions
Intervention 1: for control group: Standardized Placebo, quite similar to synbiotic capsules, twice/day by oral , for 3 months
Additionally, training low calorie diet will be taught for this group in baseline and in the end of 6th week. Intervention 2: for intervention group: Synbiotic Dietary Supplement, 500 mg capsule, twic
Additionally, training low calorie diet will be taught for this group in baseline and in the end of 6th week.
Placebo
Treatment - Drugs
for control group: Standardized Placebo, quite similar to synbiotic capsules, twice/day by oral , for 3 months
for intervention group: Synbiotic Dietary Supplement, 500 mg capsule, twice/day by oral, for 3 months
Sponsors
Vice – Chancellery of Research & Technology Affairs of Kermanshah University of Medical Sciences
ZistTakhmir Pharmaceutical Company
Eligibility
Sex/Gender
All
Age
24 Years to 64 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Filling the consent form of the present project in the beginning of study; lack of any kinds of chronic diseases such as diabetes, renal diseases, tuberculosis, liver diseases and/or the history of cardiac surgeries; possessing at least 3 items of all the 5 indexes of metabolic syndrome (based on the definition by NCEP ATP III) (in case of insulin resistance, patients must have fasting blood glucose less than 126 mg/dL); lack of taking medication to control blood glucose, blood lipid and hypertension in the beginning of study ; the age range is between 25 to 65 year; lack of injecting/receiving insulin so as to blood glucose control in the beginning of study. Exclusion criteria: Lack of regular taking the given supplements; lack of following the given diet; starting taking medication or supplements that may be affect the results of test of investigated factors or oral contraceptives, estrogen, progesterone and corticosteroids; pregnancy; weaning, receiving insulin or tablet to control the blood glucose; losing any of inclusion criteria during the time of conducting the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure. Timepoint: base line, at the end of 6th week and aftar 3 months of begin. Method of measurement: in term of mm Hg by Mercury barometers.;Plasma HDL-C. Timepoint: base line and aftar 3 months of begin. Method of measurement: in term of mg/ dL by biochemical kits.;Plasma TG. Timepoint: base line and aftar 3 months of begin. Method of measurement: in term of mg/ dL by biochemical kits.;Waist Circumference. Timepoint: base line, at the end of 6th week and aftar 3 months of begin. Method of measurement: in term of centimeter by Tape measure. | — |
Secondary
| Measure | Time frame |
|---|---|
| LDL-C. Timepoint: baseline and after 3th month. Method of measurement: in term of mg/ dL, by using biochemical kits.;Total Cholesterol. Timepoint: baseline and after 3th month. Method of measurement: in term of mg/ dL, by using biochemical kits.;Body Fat Mass. Timepoint: baseline, at the end of 6th week and after 3th month. Method of measurement: in term of kg, by usig body analyzer instrument.;Body Fat Free Mass. Timepoint: baseline, at the end of 6th week and after 3th month. Method of measurement: in term of kg, by usig body analyser instrument.;Body Mass Index (BMI). Timepoint: baseline, at the end of 6th week and after 3th month. Method of measurement: in term of kg/ m2.;Weight. Timepoint: baseline, at the end of 6th week and after 3th month. Method of measurement: in term of kg by using standardized scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFateme Rahimi
Public Health faculty of Kermanshah University of Medical Sciences
Outcome results
None listed